| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000367745 |
| P932 | PMC publication ID | 5397109 |
| P2093 | author name string | Kudo Masatoshi | |
| P2860 | cites work | Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors | Q24630594 |
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. | Q30512830 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study | Q33904007 | ||
| Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model | Q33927761 | ||
| Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Q34093919 | ||
| The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 | ||
| A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. | Q34559241 | ||
| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade | Q35065472 | ||
| Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience | Q35469004 | ||
| Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model | Q36006339 | ||
| Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice | Q36009272 | ||
| Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases | Q36954705 | ||
| Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 | ||
| Laparoscopic radiofrequency ablation for hepatocellular carcinoma | Q37582529 | ||
| A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis | Q37710955 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Immune control in hepatocellular carcinoma development and progression: role of stromal cells | Q38264953 | ||
| Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study | Q38381235 | ||
| Advances in targeted therapies for hepatocellular carcinoma in the genomic era. | Q38521011 | ||
| Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription | Q38949481 | ||
| Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. | Q39896037 | ||
| Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. | Q41489415 | ||
| Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. | Q41651668 | ||
| Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib | Q42177014 | ||
| Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification | Q43678782 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 | ||
| Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers | Q44757237 | ||
| Survival after sorafenib: expect the unexpected | Q44850851 | ||
| Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | Q45847529 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. | Q46107681 | ||
| Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations | Q46743936 | ||
| Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma | Q47370771 | ||
| Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways | Q47624575 | ||
| Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. | Q51039388 | ||
| Clinicopathological significance of 'subtypes with stem-cell feature' in combined hepatocellular-cholangiocarcinoma. | Q51147978 | ||
| Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. | Q53366237 | ||
| Hepatic 'stem cell' malignancies in adults: four cases. | Q53376535 | ||
| Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B | Q58235862 | ||
| P433 | issue | Suppl 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 1-257 | |
| P577 | publication date | 2015-07-03 | |
| P1433 | published in | Liver cancer | Q26842090 |
| P1476 | title | The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015): Evidence and Consensus on HCC Management | |
| P478 | volume | 4 |
Search more.